Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning
Rhea-AI Filing Summary
Jasper Therapeutics, Inc. (JSPR) reports that on August 21, 2026 it received a Nasdaq notice that, based on stockholders’ equity reported in its June 30, 2026 Form 10-Q, it no longer meets the $2,500,000 minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market under Rule 5550(b)(1).
The notice has no immediate effect on trading while Jasper remains in compliance with other continued listing standards. The company has 45 days, until October 5, 2026, to submit a compliance plan and may receive up to 180 days from August 21, 2026 to regain compliance if Nasdaq accepts the plan. Jasper currently anticipates seeking stockholder approval to convert outstanding Non-Voting Convertible Preferred Stock at a special stockholder meeting as part of regaining compliance, but states there is no assurance that approvals will be obtained, that Nasdaq will accept its plan, or that it will ultimately maintain its Nasdaq listing.
Positive
- None.
Negative
- Nasdaq deficiency notice and delisting risk: Jasper Therapeutics no longer satisfies Nasdaq Capital Market’s $2,500,000 stockholders’ equity requirement, must submit a compliance plan by October 5, 2026, and may face suspension or delisting if it cannot regain compliance or secure favorable outcomes from any Nasdaq panel hearing.
Filing Explained
If Nasdaq rejects Jasper’s compliance plan, or Jasper fails to regain compliance during an accepted extension, the company can request a hearing, and that request would stay suspension or delisting while the hearing process and any additional extension period run, keeping its securities listed and eligible for trading at least during that process.
8-K Event Classification
Item 1.01 — Entry into a Material Definitive Agreement
1 item
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Key Figures
Minimum stockholders’ equity requirement: $2,500,000
Compliance plan submission window: 45 calendar days
Maximum extension to regain compliance: 180 calendar days
+3 more
6 metrics
Minimum stockholders’ equity requirement
$2,500,000
Nasdaq Capital Market continued listing requirement under Listing Rule 5550(b)(1)
Compliance plan submission window
45 calendar days
Time from August 21, 2026 notice to submit plan, ending October 5, 2026
Maximum extension to regain compliance
180 calendar days
Possible extension period from August 21, 2026 if plan accepted by Nasdaq
Warrant exercise price
$115.00 per share
Each ten JSPRW redeemable warrants exercisable for one share of Voting Common Stock
Par value of Voting Common Stock
$0.0001 per share
Par value of Jasper Therapeutics Voting Common Stock
Notice date from Nasdaq
August 21, 2026
Date Nasdaq notified Jasper of non-compliance with stockholders’ equity requirement
Key Terms
stockholders’ equity, Nasdaq Listing Rule 5550(b)(1), Nasdaq Marketplace Rule 5810(c)(2)(C), Non-Voting Convertible Preferred Stock, +1 more
5 terms
stockholders’ equity financial
"based on the stockholders’ equity reported in the Company’s Quarterly Report"
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
Nasdaq Listing Rule 5550(b)(1) regulatory
"requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)"
Nasdaq Marketplace Rule 5810(c)(2)(C) regulatory
"Pursuant to Nasdaq Marketplace Rule 5810(c)(2)(C), the Company has 45 calendar days"
Non-Voting Convertible Preferred Stock financial
"approval of the conversion of its outstanding shares of Non-Voting Convertible Preferred Stock"
A non-voting convertible preferred stock is a share that normally pays a fixed dividend and takes priority over common stock for payouts, but does not grant the holder the right to vote on corporate matters. It can be exchanged later for a set number of common shares, offering the potential to participate in price gains without immediate control—like holding a high-yield loan that can be turned into equity, which matters to investors weighing steady income, upside potential, and possible dilution of ownership.
Hearing Panel regulatory
"the Company will have the right to a hearing before Nasdaq’s Hearing Panel"
A hearing panel is a small group of officials from a stock exchange, regulator or independent adjudicatory body that listens to evidence and arguments about rule breaches, disciplinary actions, listing eligibility or market disputes. Like a neighborhood board deciding whether a property meets community rules, the panel’s rulings can impose fines, trading suspensions or delisting, which can directly affect a company’s share price, liquidity and investor confidence.
FAQ
Why did Jasper Therapeutics (JSPR) receive a Nasdaq notice?
Jasper Therapeutics received a Nasdaq notice on August 21, 2026 because the stockholders’ equity reported in its Form 10-Q for the period ended June 30, 2026 no longer meets the $2,500,000 minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1).
Does the Nasdaq notice immediately affect trading in JSPR stock?
No. The company states the Nasdaq notice has no immediate effect on the continued listing or trading of its common stock on The Nasdaq Capital Market, as long as it remains in compliance with the exchange’s other continued listing requirements.
What deadline does Jasper Therapeutics (JSPR) have to submit a Nasdaq compliance plan?
Under Nasdaq Marketplace Rule 5810(c)(2)(C), Jasper Therapeutics has 45 calendar days from the notice, or until October 5, 2026, to submit a plan to regain compliance with the $2,500,000 stockholders’ equity requirement.
How long could Jasper Therapeutics have to regain Nasdaq compliance?
If Nasdaq accepts the company’s compliance plan, Jasper Therapeutics may be granted an extension of up to 180 calendar days from August 21, 2026 to regain compliance with the stockholders’ equity requirement for The Nasdaq Capital Market.
What actions does Jasper Therapeutics (JSPR) anticipate to regain Nasdaq equity compliance?
Jasper currently anticipates seeking stockholder approval to convert its outstanding Non-Voting Convertible Preferred Stock at a special stockholder meeting, which it believes could help it regain compliance, but it cautions there is no assurance the approvals or compliance will be achieved.
What happens if Jasper Therapeutics’ Nasdaq compliance plan is not accepted?
If Nasdaq does not accept the plan, or the company fails to regain compliance within any extension, Jasper would have the right to a hearing before a Nasdaq Hearing Panel. A timely hearing request would stay suspension or delisting while the hearing and any additional extension period are pending.
What securities of Jasper Therapeutics (JSPR) are listed on Nasdaq and at what warrant exercise price?
Jasper Therapeutics lists its Voting Common Stock (symbol JSPR) and Redeemable Warrants (symbol JSPRW) on The Nasdaq Stock Market. Each ten warrants are exercisable for one share of Voting Common Stock at an exercise price of $115.00 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
